Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Post by deninsaskon Feb 22, 2007 10:40am
401 Views
Post# 12287355

Why Develop Regenerative Medicine??

Why Develop Regenerative Medicine?? Some do not understand HOW our Islet Cell Neogenesis Drug E1-INT can benefit the patient if there is only a reduction in insulin usage and not a complete cure. The facts of the matter are that its the long term complications of DB that ends up killing even if insulin does seem to give good quality of life. The Diabetic Complications 5 - 10 years after Diagnosis are: -----Infection -----Blndness -----Stroke -----Kidney Disease -----Amputation -----Heart Attack -----Artherosclerosis Approximately 1 in 10 will die from one or more of these complications. It is the view that by getting the patients own body to create it's own insulin producing cells that the amount and degree of complications will be drastically reduced even if most never achieve 100% independance from the needle. Novo will option to further develop this because a decrease in mortality will offset any decrease in use of their insulin products and an increase in the quality of life of the patient as a result of fewer complications is paramount.
Bullboard Posts